Enzalutamide
Total Payments
$4.7M
Transactions
398
Doctors
53
Companies
4
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2017 | $4.7M | 398 | 53 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $4.6M | 276 | 97.7% |
| Consulting Fee | $71,795 | 20 | 1.5% |
| Travel and Lodging | $27,155 | 47 | 0.6% |
| Space rental or facility fees (teaching hospital only) | $5,000 | 2 | 0.1% |
| Food and Beverage | $3,458 | 53 | 0.1% |
Payments by Type
Research
$4.6M
276 transactions
General
$107,408
122 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Randomized Study of Enzalutamide in Patients With Localized Prostate Cancer Undergoing Active Surveillance (ENACT) | Astellas Pharma Global Development | $820,821 | 3 |
| A Prospective Observational Cohort Study of Patients With Castration-Resistant Prostate Cancer (CRPC) in the United States | Astellas Pharma Global Development | $814,171 | 5 |
| Feasibility study of adjuvant enzalutamide for the treatment of early stage AR(+) triple negative breast cancer | Astellas Pharma Global Development | $265,748 | 0 |
| Randomized Phase II screening trial of enzalutamide/MDV-3100 and LHRH analogue vs combined androgen deprivation (LHRH analogue + bicalutamide) in metastatic hormone sensitive prostate cancer | Astellas Pharma Global Development | $264,000 | 0 |
| A Phase II Trial of Enzalutamide in Patients with Androgen Receptor Positive (AR+) Ovarian, Primary Peritoneal and Fallopian Tube Cancer and One, Two or Three Prior Therapies | Astellas Pharma Global Development | $207,671 | 0 |
| A Phase II Study of Enzalutamide Plus Dutasteride as First Line Treatment for Patients ? 65 Years with Systemic Prostate Cancer | Astellas Pharma Global Development | $180,260 | 0 |
| Enzalutamide and Metformin Combination Therapy to Overcome Autophagy Resistance in CRPC | Astellas Pharma Global Development | $174,296 | 0 |
| A Phase I/II Trial of Concurrent Chemohormonal Therapy Using Enzalutamide (MDV-3100) and Cabazitaxel in Patients with Metastatic Castration Resistant Prostate Cancer | Astellas Pharma Global Development | $165,033 | 0 |
| Molecular Mechanisms Underlying Tumor Progression Despite Enzalutamide Treatment | Astellas Pharma Global Development | $160,834 | 0 |
| EXTEND: Safety and Efficacy of EXercise Training in Men Receiving ENzalutamide in Combination with Conventional Androgen Deprivation Therapy for Hormone Naive Prostate Cancer | Astellas Pharma Global Development | $132,537 | 0 |
| Phase II Randomized Placebo-Controlled Double-Blind Study of Salvage Radiation Therapy (SRT) Plus Placebo Versus SRT Plus Enzalutamide in Men with High-Risk PSA-Recurrent Prostate Cancer after Radical Prostatectomy | Astellas Pharma Global Development | $128,977 | 0 |
| A Phase 2 Open-label Extension Study to Assess the Safety of Continued Administration of MDV3100 in Subjects With Prostate Cancer Who Showed Benefit From Prior Exposure to MDV3100 | Astellas Pharma Europe BV | $119,580 | 0 |
| A phase II randomized study of enzalutamide/leuprolide versus enzalutamide/leuprolide plus abiraterone/prednisone as neoadjuvant therapy for localized intermediate-high risk prostate cancer undergoing prostatectomy | Astellas Pharma Global Development | $99,361 | 0 |
| Metabolic complications in patients treated with enzalutamide vs standard ADT for the treatment of advanced prostate cancer | Astellas Pharma Global Development | $87,507 | 0 |
| Androgen receptor blockade as a novel radiosensitization strategy in AR-positive, triplenegativebreast cancer | Astellas Pharma Global Development | $82,298 | 0 |
| Characterizing AR negative NEPC as a mechanism of resistance to enzalutamide | Astellas Pharma Global Development | $78,824 | 0 |
| Phase II trial of enzalutamide for castrate-resistant prostate cancer (CRPC) with correlative assessment of androgen receptor (AR) signaling and whole-exome and transcriptome sequencing | Astellas Pharma Global Development | $78,647 | 0 |
| Comparing CRPC Patients Outcomes between an Advanced Prostate Cancer Center and the Primary Urology Office | Astellas Pharma Global Development | $77,420 | 0 |
| Enzalutamide with External Beam Radiation for Intermediate Risk Prostate Cancer: A Phase II study | Astellas Pharma Global Development | $74,825 | 0 |
| Phase Ib trial of Enzalutamide in combination with radiation therapy and LHRH agonist therapy in the management of intermediate and high-risk prostate cancer | Astellas Pharma Global Development | $67,699 | 0 |
Top Doctors Receiving Payments for Enzalutamide
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Lebanon, NH | $4.5M | 215 |
| , MD | Hematology & Oncology | Seattle, WA | $21,072 | 15 |
| , MD | Student in an Organized Health Care Education/Training Program | Hendersonville, TN | $5,762 | 5 |
| , DR | Urology | Myrtle Beach, SC | $5,736 | 13 |
| , MD | Hematology & Oncology | Plano, TX | $5,487 | 3 |
| , M.D | Urology | Melrose Park, IL | $5,331 | 4 |
| , MD | Urology | Oxnard, CA | $5,120 | 4 |
| , MD | Urology | Greenbelt, MD | $5,111 | 6 |
| , M.D | Hematology & Oncology | Wichita, KS | $4,876 | 6 |
| , MD | Medical Oncology | San Antonio, TX | $4,775 | 4 |
| , MD | Hematology & Oncology | Palestine, TX | $4,488 | 5 |
| , M.D | Urology | Fresno, CA | $4,432 | 5 |
| , MD | Urology | Cleveland, OH | $4,399 | 4 |
| , M.D | Urology | San Luis Obispo, CA | $4,332 | 5 |
| , MD | Urology | Cincinnati, OH | $4,288 | 3 |
| , M.D | Medical Oncology | Mesa, AZ | $4,263 | 5 |
| , M.D | Internal Medicine | Casper, WY | $4,162 | 5 |
| , M.D | Urology | Burbank, CA | $4,090 | 4 |
| , M.D | Urology | Las Vegas, NV | $3,796 | 5 |
| , M.D | Urology | Nashville, TN | $3,679 | 8 |
| , M.D | Urology | Baltimore, MD | $3,419 | 5 |
| , M.D | Hematology & Oncology | Denver, CO | $3,241 | 3 |
| , MD | Hematology & Oncology | Aurora, CO | $2,289 | 1 |
| Anthony Tolcher | Medical Oncology | San Antonio, TX | $2,289 | 1 |
| William Clark | Urology | Anchorage, AK | $2,159 | 4 |
Ad
Manufacturing Companies
- Astellas Pharma Global Development $4.4M
- Astellas Pharma Europe BV $119,580
- Astellas Pharma US Inc $87,481
- Astellas Pharma Inc $19,112
Product Information
- Type Drug
- Total Payments $4.7M
- Total Doctors 53
- Transactions 398
About Enzalutamide
Enzalutamide is a drug associated with $4.7M in payments to 53 healthcare providers, recorded across 398 transactions in the CMS Open Payments database. The primary manufacturer is Astellas Pharma Global Development.
Payment data is available from 2017 to 2017. In 2017, $4.7M was paid across 398 transactions to 53 doctors.
The most common payment nature for Enzalutamide is "Unspecified" ($4.6M, 97.7% of total).
Enzalutamide is associated with 20 research studies, including "A Randomized Study of Enzalutamide in Patients With Localized Prostate Cancer Undergoing Active Surveillance (ENACT)" ($820,821).